Encap Drug Delivery Adds New Commercial Product to Portfolio

Encap Drug Delivery, the world’s leading contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules, recerntly announced the addition of a further pharmaceutical product to its portfolio of commercial products. The privately held company, founded 23 years ago, has spent the past few years building its development services capability and has state-of-the-art manufacturing facilities based in Livingston (United Kingdom). The company has been successfully audited by the European MHRA and USA FDA and has over 70 staff totally dedicated to the liquid fill hard capsule technology.

The company has development and commercial contracts with a large number of pharmaceutical and biotech clients across the major pharmaceutical markets (Europe, US, and Japan) and is now benefiting from the progression of these products through the development phase and into commercial manufacture.

Dr. Stephen Brown (CEO) commented that he was delighted to have secured the commercial manufacturing contract for a proprietary pharmaceutical product that is currently licensed in Europe and is transferring to Encap from the existing CDMO. “This is a large-volume, licensed pharmaceutical, and the award of this contract demonstrates that in addition to its excellent development services capability, the company is able to provide a best-in-class commercially competitive manufacturing service.”

Encap is working closely with its client to prepare for the successful launch of this and other pharmaceutical products in 2012.

Dr. Brown indicated that the company had now firmly established its credentials as an excellent development services and drug delivery partner (now 50% of the company’s revenues) and is now well placed to continue the expansion of its commercial manufacturing business. The company currently manufactures 10 commercial products and following the expansion of the manufacturing facility in 2008, the company strategy will be to add further commercial products in the coming years. This includes highly potent compounds or those which require special handling as the company now has dedicated high-containment facilities within its Livingston site.

Encap was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing, and high-volume commercial manufacturing. Encap’s state-of-the-art facility in the UK is the world’s largest development and manufacturing facility dedicated to liquid and semi-solid filled hard capsules.